Providing plant extracts in a suitable delivery form is the challenging task for Schwabe's formulation development unit.
On the one hand, the drug has to maintain its quality throughout the given shelf-life. On the other hand, the active ingredients must be released at the right time and at the right place to develop their beneficial action.
The company's highly-concentrated special extracts and advanced manufacturing processes for solid dosage forms have resulted in substantial progress in formulation development, leading to high-dose preparations in modern pharmaceutical forms.
Excipients used for the finished product may have a significant influence on the bioavailability of the active substance and on the stability of the medicinal product, and must be completely safe for human use.
All these factors are taken into account when developing new pharmaceutical forms. The finished preparations, small film-coated tablets, effervescent tablets, microtablets, sustained release formulations or enteric-coated capsules, are easy to take, encourage patient compliance and consequently further therapeutic objectives.
Schwabe's high-dosage concept reduces intake frequency and is therefore particularly suitable for elderly patients.